Cover Image
市場調查報告書

SignPath Pharma Inc的產品平台分析

SignPath Pharma Inc - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 308911
出版日期 內容資訊 英文 27 Pages
訂單完成後即時交付
價格
Back to Top
SignPath Pharma Inc的產品平台分析 SignPath Pharma Inc - Product Pipeline Review - 2015
出版日期: 2015年07月08日 內容資訊: 英文 27 Pages
簡介

SignPath Pharma Inc是開發及製造基於薑黃素衍生物的新治療藥之生物醫藥品企業。

本報告提供SignPath Pharma Inc的藥劑開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的藥物評估,最新的開發平台趨勢,暫停中的計劃等資訊。

SignPath Pharma Inc的基本資料

SignPath Pharma Inc概要

  • 主要資訊
  • 企業資料

SignPath Pharma Inc:R&D概要

  • 主要的治療範圍

SignPath Pharma Inc:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品

SignPath Pharma Inc:開發中產品概況

  • 臨床實驗階段的開發中產品
    • 第一階段的產品/聯合治療模式
  • 初期階段的開發中產品
  • IND/CTA Filed Products/Combination Treatment Modalities
    • 前臨床階段的產品/聯合治療模式

SignPath Pharma Inc:藥物簡介

  • Liposomal Curcumin
  • EU-8120
  • Liposomal PLGA Curcumin
  • Nanocurcumin

SignPath Pharma Inc:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

SignPath Pharma Inc:最近的開發平台趨勢

SignPath Pharma Inc:暫停中的計劃

SignPath Pharma Inc:總公司和子公司的所在地

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07352CDB

Summary

Global Markets Direct's, 'SignPath Pharma Inc - Product Pipeline Review - 2015', provides an overview of the SignPath Pharma Inc's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of SignPath Pharma Inc's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of SignPath Pharma Inc including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of SignPath Pharma Inc's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the SignPath Pharma Inc's pipeline products

Reasons to buy

  • Evaluate SignPath Pharma Inc's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of SignPath Pharma Inc in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the SignPath Pharma Inc's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of SignPath Pharma Inc and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of SignPath Pharma Inc
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of SignPath Pharma Inc and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • SignPath Pharma Inc Snapshot
    • SignPath Pharma Inc Overview
    • Key Information
    • Key Facts
  • SignPath Pharma Inc - Research and Development Overview
    • Key Therapeutic Areas
  • SignPath Pharma Inc - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • SignPath Pharma Inc - Pipeline Products Glance
    • SignPath Pharma Inc - Clinical Stage Pipeline Products
      • Phase I Products/Combination Treatment Modalities
    • SignPath Pharma Inc - Early Stage Pipeline Products
      • IND/CTA Filed Products/Combination Treatment Modalities
      • Preclinical Products/Combination Treatment Modalities
  • SignPath Pharma Inc - Drug Profiles
    • Liposomal Curcumin
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • EU-8120
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Liposomal PLGA Curcumin
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Nanocurcumin
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • SignPath Pharma Inc - Pipeline Analysis
    • SignPath Pharma Inc - Pipeline Products by Target
    • SignPath Pharma Inc - Pipeline Products by Route of Administration
    • SignPath Pharma Inc - Pipeline Products by Molecule Type
    • SignPath Pharma Inc - Pipeline Products by Mechanism of Action
  • SignPath Pharma Inc - Recent Pipeline Updates
  • SignPath Pharma Inc - Dormant Projects
  • SignPath Pharma Inc - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • SignPath Pharma Inc, Key Information
  • SignPath Pharma Inc, Key Facts
  • SignPath Pharma Inc - Pipeline by Indication, 2015
  • SignPath Pharma Inc - Pipeline by Stage of Development, 2015
  • SignPath Pharma Inc - Monotherapy Products in Pipeline, 2015
  • SignPath Pharma Inc - Phase I, 2015
  • SignPath Pharma Inc - IND/CTA Filed, 2015
  • SignPath Pharma Inc - Preclinical, 2015
  • SignPath Pharma Inc - Pipeline by Target, 2015
  • SignPath Pharma Inc - Pipeline by Route of Administration, 2015
  • SignPath Pharma Inc - Pipeline by Molecule Type, 2015
  • SignPath Pharma Inc - Pipeline Products by Mechanism of Action, 2015
  • SignPath Pharma Inc - Recent Pipeline Updates, 2015
  • SignPath Pharma Inc - Dormant Developmental Projects,2015

List of Figures

  • SignPath Pharma Inc - Pipeline by Top 10 Indication, 2015
  • SignPath Pharma Inc - Pipeline by Stage of Development, 2015
  • SignPath Pharma Inc - Monotherapy Products in Pipeline, 2015
  • SignPath Pharma Inc - Pipeline by Top 10 Route of Administration, 2015
  • SignPath Pharma Inc - Pipeline by Top 10 Molecule Type, 2015
Back to Top